Showing results (21-30 of 499) with videos related to
Sort By:
Pageof 50
AIDS (London, England)|March 28, 2003
IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopeniaGuislaine Carcelain, Pierre Saint-Mézard, Hester Korthals Altes, et al.AIDS (London, England)|October 22, 2010
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patientsAna Canestri, Anne Krivine, Lambert Assoumou, et al.AIDS (London, England)|May 12, 2017
Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individualsMorgane Griesbeck, Marc-Antoine Valantin, Karine Lacombe, et al.Current Infectious Disease Reports|October 18, 2005
The HIV infection and immune activation: "to fight and burn"Victor Appay, François Boutboul, Brigitte AutranCurrent Opinion in HIV and AIDS|March 16, 2013
Immune control of HIV-1 reservoirsBrigitte Autran, Benjamin Descours, Charline BacchusAIDS (London, England)|July 18, 2015
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremiaAmélie Guihot, Chiara Dentone, Lambert Assoumou, et al.AIDS (London, England)|February 27, 2015
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremiaLaure Campillo-Gimenez, Lambert Assoumou, Marc-Antoine Valantin, et al.AIDS (London, England)|November 2, 2005
Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMVFrançois Boutboul, Denis Puthier, Victor Appay, et al.Current Opinion in HIV and AIDS|April 18, 2009
Clinical trials for heavily pretreated patients: update in 2006Christine Katlama, Jade GhosnExpert Opinion on Investigational Drugs|March 3, 2012
Dolutegravir for the treatment of HIVChristine Katlama, Robert MurphyPageof 50